BD Physioject allows self-injection of drugs for chronic diseases

Disposable device offers one-button activation and needle protection after injection

The BD Physioject disposable auto-injector is for self-injection of drugs for chronic diseases

The BD Physioject disposable auto-injector from BD Medical, a division of Becton, Dickinson and Company (BD), is for self-injection of drugs for chronic diseases such as rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis.

The auto-injector offers easy, one-button activation, 360° view of the drug and injection process, visual confirmation of the end of injection, and protection of the needle after injection.

BD Physioject can be customised to offer a modified external design, flexible injection duration, a range of possible subcutaneous injection depths, and various syringe options (such as an end-of-dose indicator). It also includes a straightforward two-part assembly process that simplifies production and manufacturing.

The device is used in combination with the BD Hypak for Biotech syringe, a primary container for biologics, to provide a low level of interaction with such drugs.

Merck Serono uses Physioject as the platform for RebiDose, the Rebif pre-filled pen, for the treatment of multiple sclerosis. RebiDose was approved in Europe and Australia in October 2010.

Companies